Streetbeat News

Products Services

AAPL

QCOM

SSNLF

Samsung's upcoming chipset, the Exynos 2400, is reported to be less powerful than Apple's A17 Pro chipset and Qualcomm's Snapdragon 8 Gen 2 chipset. The Exynos 2400 will be used in the Galaxy S24 in certain markets, while the Snapdragon 8 Gen 3 will be used in the US. The A17 Pro chipset is said to be over 30% more powerful than the Snapdragon 8 Gen 3 chipset in single-core performance. This could impact the performance of Samsung's Galaxy S24, scheduled to launch in 2024.

Portfolio Pulse from Rounak Jain

October 05, 2023 | 12:59 pm

CVM

CEL-SCI Corporation (NYSE:CVM) has filed a request with the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for approval of Multikine immunotherapy for the treatment of newly diagnosed head and neck cancer. The company will present new results demonstrating superior pre-surgical response rates and overall survival advantages. CEL-SCI is seeking a pathway towards approval of Multikine throughout the UK and plans to apply for marketing authorization as soon as possible.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 12:47 pm

GRI

GRI Bio has announced the publication of a comprehensive review in Frontiers in Immunology, demonstrating the key role of Type 1 iNKT cells in modulating various fibrotic conditions. The data supports GRI Bio's leading NKT regulation technology, which targets the inflammatory cascade earlier to modulate disease progression. The company is advancing toward the launch of a Phase 2a biomarker study evaluating GRI-0621 for the treatment of IPF before the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 12:46 pm

LGVN

RIVN

VSME

VS Media is expanding into Macau, showing strong growth in digital marketing. Longeveron announced positive results for Lomecel-B™ in its Phase 2a clinical trial for Alzheimer's treatment. Rivian Automotive shares dropped after announcing a $1.5 billion proposed green convertible senior notes offering and preliminary Q3 revenue estimates.

Portfolio Pulse from ryanfaloona@benzinga.com

October 05, 2023 | 12:46 pm

AMPX

Amprius Technologies (NYSE:AMPX), a leader in lithium-ion batteries, has secured a purchase order from an eVTOL (electric vertical take-off and landing) manufacturer for custom silicon anode cells. The company's advanced cells will serve all major segments of the growing aviation market for electric mobility. The agreement is contingent upon the successful qualification of sample custom cells to be delivered later this year. Following successful qualification, the eVTOL manufacturer would receive an increased number of custom samples in early 2024 for their demonstrator integration.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 12:45 pm

CDAY

Ceridian HCM Holding Inc launched a range of offerings including Dayforce Autonomous Payroll, Dayforce Exchange, Dayforce Co-Pilot, and Dayforce Alumni Network at its annual customer conference. The new offerings aim to modernize payroll processing and elevate user experience with AI-powered features. Needham upgraded Ceridian HCM Holding to Buy, with a price target of $82. CDAY shares traded higher by 2.14% premarket on the last check Thursday.

Portfolio Pulse from Anusuya Lahiri

October 05, 2023 | 12:45 pm

DDD

3D Systems (NYSE:DDD) has announced the MJP 300W and VisiJet® Wax Jewel Ruby, two additions to its portfolio of solutions for jewelry manufacturing. The MJP 300W is a wax 3D printer designed to enhance productivity, efficiency, and design freedom in jewelry manufacturing workflows. The VisiJet Wax Jewel Ruby is a temperature-stable pure wax material that maintains intricate jewelry designs during the molding process. The global 3D-printed jewelry market is expected to exceed $22 billion by 2030.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 12:44 pm

COSM

Cosmos Health Inc. (NASDAQ:COSM) CEO Greg Siokas has issued a letter to shareholders outlining the company's strategic plans and financial outlook. The company has introduced its 2026 guidance, expecting to achieve over $180M in gross annual revenue and EBITDA in excess of $20M. The company has completed three acquisitions in 2023 and is making progress in R&D. The company is also considering spinning off its R&D division into a standalone, publicly listed biotech company. The CEO has invested more than $15M since inception, including almost $1M YTD.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 12:43 pm

DYAI

Dyadic International (NASDAQ:DYAI) has entered into a research collaboration agreement with the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital and Voltron Therapeutics. The collaboration is part of a $5.88 million award from the U.S. Department of Defense to VIC for the development of a Self-Assembling Vaccine (SAV) Platform for rapid production of prophylactic vaccines. Dyadic's proprietary C1 protein production platform will be used to express vaccine antigens for influenza A and other infectious diseases. If successful, this collaboration could provide a commercial opportunity for Dyadic to receive revenues from products brought to market.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 12:42 pm

INBS

Intelligent Bio Solutions Inc. (NASDAQ:INBS) announced that VKVP Haulage, a specialist container logistics firm, has adopted its Intelligent Fingerprinting Drug Screening System. The system will be used for random in-house drug testing to complement VKVP's existing alcohol testing program. Additionally, INBS announced that Auctus Management Group, an existing client, has successfully completed 25,000 tests using the Intelligent Fingerprinting system.

Portfolio Pulse from Benzinga Newsdesk

October 05, 2023 | 12:41 pm